NASDAQ:LGND Ligand Pharmaceuticals - LGND Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. $71.68 -0.48 (-0.67%) (As of 03/20/2023 12:00 AM ET) Add Compare Share Share Today's Range$70.76▼$73.9550-Day Range$67.34▼$77.0852-Week Range$57.77▼$121.66Volume118,388 shsAverage Volume144,351 shsMarket Capitalization$1.22 billionP/E RatioN/ADividend YieldN/APrice Target$119.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Ligand Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside66.0% Upside$119.00 Price TargetShort InterestBearish5.23% of Float Sold ShortDividend StrengthN/ASustainability-1.57Upright™ Environmental ScoreNews Sentiment0.87Based on 2 Articles This WeekInsider TradingN/AProj. Earnings Growth-0.48%From $2.10 to $2.09 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.11 out of 5 starsMedical Sector379th out of 988 stocksPharmaceutical Preparations Industry166th out of 482 stocks 3.5 Analyst's Opinion Consensus RatingLigand Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $119.00, Ligand Pharmaceuticals has a forecasted upside of 66.0% from its current price of $71.68.Amount of Analyst CoverageLigand Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.23% of the float of Ligand Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverLigand Pharmaceuticals has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Ligand Pharmaceuticals has recently increased by 2.47%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldLigand Pharmaceuticals does not currently pay a dividend.Dividend GrowthLigand Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreLigand Pharmaceuticals has received a 67.85% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Antihypertensives (C02)", "Pneumococcal vaccines", "Quinolones", "Fosphenytoin", "Antifungal medication (D01) ", and "Bevacizumab" products. See details.Environmental SustainabilityThe Environmental Impact score for Ligand Pharmaceuticals is -1.57. Previous Next 2.7 News and Social Media Coverage News SentimentLigand Pharmaceuticals has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.35 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Ligand Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for LGND on MarketBeat in the last 30 days. This is a decrease of -94% compared to the previous 30 days.MarketBeat Follows2 people have added Ligand Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ligand Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders10.40% of the stock of Ligand Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions87.16% of the stock of Ligand Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Ligand Pharmaceuticals are expected to decrease by -0.48% in the coming year, from $2.10 to $2.09 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ligand Pharmaceuticals is -36.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ligand Pharmaceuticals is -36.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioLigand Pharmaceuticals has a PEG Ratio of 1.38. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioLigand Pharmaceuticals has a P/B Ratio of 2.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Ligand Pharmaceuticals (NASDAQ:LGND) StockLigand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.Read More Receive LGND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address LGND Stock News HeadlinesMarch 17, 2023 | finance.yahoo.comHow Much Upside is Left in Ligand (LGND)? Wall Street Analysts Think 49.11%March 9, 2023 | finance.yahoo.comSermonix Pharmaceuticals Announces Initiation of Phase 3 ELAINE-3 Study of Lasofoxifene Plus Abemaciclib in Pre- and Post-Menopausal Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation as Detected by Guardant Health’s Guardant360 CDx Liquid BiopsyMarch 21, 2023 | Investing Daily (Ad)How This Trader Banked A 97% Win RateDespite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. March 6, 2023 | finance.yahoo.comSermonix’s Lasofoxifene Improves Vaginal/Vulvar Symptoms Relative to Fulvestrant in ELAINE 1 Study of Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2- Breast Cancer and an ESR1 MutationMarch 3, 2023 | finance.yahoo.comLigand Pharmaceuticals Full Year 2022 Earnings: Revenues Beat Expectations, EPS LagsMarch 1, 2023 | seekingalpha.comOmniAb: Legitimate Competition To AbCellera In Antibody DiscoveryFebruary 23, 2023 | finance.yahoo.comLigand's (LGND) Q4 Sales & Earnings Top, View Raised, Stock UpFebruary 22, 2023 | msn.comLigand Pharmaceuticals Non-GAAP EPS of $1.36 beats by $0.24, revenue of $50.38M beats by $10.75MMarch 21, 2023 | Investing Daily (Ad)How This Trader Banked A 97% Win RateDespite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. February 21, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND) and Seagen (SGEN)February 17, 2023 | finance.yahoo.comLigand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA NephropathyFebruary 16, 2023 | finance.yahoo.comSermonix Pharmaceuticals and Quantum Leap Healthcare Announce New Study Arm to Evaluate Lasofoxifene in Ongoing I-SPY 2 Clinical TrialFebruary 6, 2023 | finance.yahoo.comLigand to Report Fourth Quarter Financial Results on February 22January 23, 2023 | finance.yahoo.comShareholders in Ligand Pharmaceuticals (NASDAQ:LGND) are in the red if they invested five years agoJanuary 11, 2023 | finance.yahoo.comAre Options Traders Betting on a Big Move in Ligand (LGND) Stock?January 6, 2023 | finance.yahoo.comLigand’s Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum ContagiosumDecember 23, 2022 | msn.comRoth Capital Maintains Buy Rating for Ligand Pharmaceuticals: Here's What You Need To KnowDecember 19, 2022 | finance.yahoo.comAre Investors Undervaluing Ligand Pharmaceuticals (LGND) Right Now?December 13, 2022 | markets.businessinsider.comLigand Pharma Guides FY23 EPS Above View, But Revenue Shy Of EstimatesDecember 13, 2022 | finance.yahoo.comLigand Provides Highlights from its Investor and Analyst Day EventDecember 13, 2022 | finance.yahoo.comIs BioNTech (BNTX) Stock Undervalued Right Now?December 13, 2022 | finance.yahoo.comLGND or GMAB: Which Is the Better Value Stock Right Now?December 13, 2022 | finance.yahoo.comLigand Pharma Issues Mixed Guidance For FY23December 8, 2022 | finance.yahoo.comSermonix Pharmaceuticals Announces Poster Presentation on Phase 1 Ethnobridging Study of Lasofoxifene at the 12th AACR-JCA Joint Conference: Breakthroughs in Cancer Research — Translating Knowledge Into PracticeDecember 5, 2022 | marketwatch.comLigand Pharmaceuticals CEO Higgins RetiresDecember 5, 2022 | nasdaq.comIs Now The Time OmniAb? 5 Insider Purchase And Two Bullish Initiations Propel Shares Almost 100% Higher Over The WeekDecember 5, 2022 | seekingalpha.comOmniAb: Scalable Biotech Spinoff Opportunity, High Risk/High RewardSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive LGND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address LGND Company Calendar Last Earnings2/22/2023Today3/21/2023Next Earnings (Estimated)5/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:LGND CUSIP53220K50 CIK886163 Webwww.ligand.com Phone(858) 550-7500Fax858-550-1826Employees154Year FoundedN/APrice Target and Rating Average Stock Price Forecast$119.00 High Stock Price Forecast$160.00 Low Stock Price Forecast$90.00 Forecasted Upside/Downside+66.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.98) Trailing P/E RatioN/A Forward P/E Ratio34.13 P/E Growth1.38Net Income$-33,360,000.00 Net Margins-15.19% Pretax Margin18.35% Return on Equity-0.89% Return on Assets-0.67% Debt Debt-to-Equity RatioN/A Current Ratio2.67 Quick Ratio2.53 Sales & Book Value Annual Sales$196.24 million Price / Sales6.24 Cash Flow$5.06 per share Price / Cash Flow14.18 Book Value$35.37 per share Price / Book2.03Miscellaneous Outstanding Shares17,080,000Free Float15,301,000Market Cap$1.22 billion OptionableOptionable Beta1.06 Key ExecutivesTodd C. DavisChief Executive Officer & DirectorMatthew Edward KorenbergPresident & Chief Operating OfficerOctavio EspinozaChief Financial OfficerSimon LatimerInvestors Relations ManagerAudrey Warfield-GrahamChief People OfficerKey CompetitorsDynavax TechnologiesNASDAQ:DVAXMannKindNASDAQ:MNKDOPKO HealthNASDAQ:OPKGeronNASDAQ:GERNImmunoGenNASDAQ:IMGNView All CompetitorsInsiders & InstitutionsTeachers Retirement System of The State of KentuckySold 580 shares on 2/22/2023Ownership: 0.029%Macquarie Group Ltd.Bought 6,975 shares on 2/21/2023Ownership: 4.740%State of WyomingBought 668 shares on 2/16/2023Ownership: 0.004%Legal & General Group PlcBought 1,045 shares on 2/15/2023Ownership: 0.277%State of Wisconsin Investment BoardSold 535 shares on 2/15/2023Ownership: 0.097%View All Insider TransactionsView All Institutional Transactions LGND Stock - Frequently Asked Questions Should I buy or sell Ligand Pharmaceuticals stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LGND shares. View LGND analyst ratings or view top-rated stocks. What is Ligand Pharmaceuticals' stock price forecast for 2023? 4 Wall Street research analysts have issued 12 month price targets for Ligand Pharmaceuticals' stock. Their LGND share price forecasts range from $90.00 to $160.00. On average, they predict the company's share price to reach $119.00 in the next twelve months. This suggests a possible upside of 66.0% from the stock's current price. View analysts price targets for LGND or view top-rated stocks among Wall Street analysts. How have LGND shares performed in 2023? Ligand Pharmaceuticals' stock was trading at $66.80 at the start of the year. Since then, LGND stock has increased by 7.3% and is now trading at $71.68. View the best growth stocks for 2023 here. When is Ligand Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023. View our LGND earnings forecast. How were Ligand Pharmaceuticals' earnings last quarter? Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) issued its earnings results on Wednesday, February, 22nd. The biotechnology company reported $1.36 EPS for the quarter, beating analysts' consensus estimates of $1.23 by $0.13. The biotechnology company earned $50.40 million during the quarter, compared to analysts' expectations of $39.63 million. Ligand Pharmaceuticals had a negative trailing twelve-month return on equity of 0.89% and a negative net margin of 15.19%. Ligand Pharmaceuticals's revenue for the quarter was down 10.6% compared to the same quarter last year. During the same period last year, the business posted $1.34 EPS. What ETFs hold Ligand Pharmaceuticals' stock? ETFs with the largest weight of Ligand Pharmaceuticals (NASDAQ:LGND) stock in their portfolio include Invesco Dynamic Pharmaceuticals ETF (PJP), iShares Genomics Immunology and Healthcare ETF (IDNA), Virtus LifeSci Biotech Products ETF (BBP), Invesco S&P SmallCap Health Care ETF (PSCH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Franklin Genomic Advancements ETF (HELX), Pacer US Small Cap Cash Cows 100 ETF (CALF) and iShares U.S. Pharmaceuticals ETF (IHE). What guidance has Ligand Pharmaceuticals issued on next quarter's earnings? Ligand Pharmaceuticals updated its FY 2023 earnings guidance on Wednesday, February, 22nd. The company provided earnings per share (EPS) guidance of $3.30-$3.45 for the period, compared to the consensus earnings per share estimate of $3.24. The company issued revenue guidance of $120.00 million-$124.00 million, compared to the consensus revenue estimate of $130.58 million. What is John L. Higgins' approval rating as Ligand Pharmaceuticals' CEO? 1 employees have rated Ligand Pharmaceuticals Chief Executive Officer John L. Higgins on Glassdoor.com. John L. Higgins has an approval rating of 100% among the company's employees. This puts John L. Higgins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Ligand Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Cisco Systems (CSCO), Illumina (ILMN) and Gilead Sciences (GILD). What is Ligand Pharmaceuticals' stock symbol? Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND." Who are Ligand Pharmaceuticals' major shareholders? Ligand Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Macquarie Group Ltd. (4.74%), Villere ST Denis J & Co. LLC (2.86%), Dimensional Fund Advisors LP (2.71%), Stephens Investment Management Group LLC (2.69%), Chicago Capital LLC (1.89%) and abrdn plc (1.83%). Insiders that own company stock include Charles S Berkman, John L Higgins, John W Kozarich, Matthew W Foehr, Octavio Espinoza and Todd C Davis. View institutional ownership trends. How do I buy shares of Ligand Pharmaceuticals? Shares of LGND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ligand Pharmaceuticals' stock price today? One share of LGND stock can currently be purchased for approximately $71.68. How much money does Ligand Pharmaceuticals make? Ligand Pharmaceuticals (NASDAQ:LGND) has a market capitalization of $1.22 billion and generates $196.24 million in revenue each year. The biotechnology company earns $-33,360,000.00 in net income (profit) each year or ($1.98) on an earnings per share basis. How many employees does Ligand Pharmaceuticals have? The company employs 154 workers across the globe. How can I contact Ligand Pharmaceuticals? Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The official website for the company is www.ligand.com. The biotechnology company can be reached via phone at (858) 550-7500, via email at investors@ligand.com, or via fax at 858-550-1826. This page (NASDAQ:LGND) was last updated on 3/21/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.